Inflammasome activation in podocytes: a new mechanism of glomerular diseases

Abstract

Introduction

Inflammasome is a multi-protein complex which is an important constituent of innate immunity. It mainly consists of three parts, apoptosis-associated speck-like protein containing caspase recruitment domain (ASC), caspase protease, and a NOD-like receptor (NLR) family protein (such as NLRP1) or an HIN200 family protein (such as AIM2). Inflammasome is widely studied in many autoimmune diseases and chronic inflammatory reactions, such as familial periodic autoinflammatory response, type 2 diabetes, Alzheimer's disease, and atherosclerosis. Activation of inflammasome in the kidney has been widely reported in glomerular and tubular-interstitial diseases. Podocytes play a critical role in maintaining the normal structure and function of glomerular filtration barrier. Recently, it has been demonstrated that podocytes, as a group of renal residential cells, can express all necessary components of NLRP3 inflammasome, which is activated and contribute to inflammatory response in the local kidney.

Methods

Literature review was conducted to further summarize current evidence of podocyte NLRP3 inflammasome activation and related molecular mechanisms under different disease conditions.

Results

Podocytes are a key component of the glomerular filtration barrier, and the loss of podocyte regeneration is a major limiting factor in the recovery of proteinuria. Through a more comprehensive study of inflammasome in podocytes, it will provide new targets and possibilities for the treatment of kidney diseases.

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8

References

  1. 1.

    Sharma D, Kanneganti TD. The cell biology of inflammasomes: Mechanisms of inflammasome activation and regulation. J Cell Biol. 2016;213:617–29.

    CAS  PubMed  PubMed Central  Google Scholar 

  2. 2.

    Prochnicki T, Latz E. Inflammasomes on the crossroads of innate immune recognition and metabolic control. Cell Metab. 2017;26:71–93.

    CAS  PubMed  Google Scholar 

  3. 3.

    Hornung V, Ablasser A, Charrel-Dennis M, Bauernfeind F, Horvath G, Caffrey DR, et al. AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. Nature. 2009;458:514–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  4. 4.

    Brunette RL, Young JM, Whitley DG, Brodsky IE, Malik HS, Stetson DB. Extensive evolutionary and functional diversity among mammalian AIM2-like receptors. J Exp Med. 2012;209:1969–83.

    CAS  PubMed  PubMed Central  Google Scholar 

  5. 5.

    Chae JJ, Cho YH, Lee GS, Cheng J, Liu PP, Feigenbaum L, et al. Gain-of-function Pyrin mutations induce NLRP3 protein-independent interleukin-1beta activation and severe autoinflammation in mice. Immunity. 2011;34:755–68.

    CAS  PubMed  PubMed Central  Google Scholar 

  6. 6.

    Xu H, Yang J, Gao W, Li L, Li P, Zhang L, et al. Innate immune sensing of bacterial modifications of Rho GTPases by the Pyrin inflammasome. Nature. 2014;513:237–41.

    CAS  PubMed  Google Scholar 

  7. 7.

    Chang A, Ko K, Clark MR. The emerging role of the inflammasome in kidney diseases. Curr Opin Nephrol Hypertens. 2014;23:204–10.

    CAS  PubMed  PubMed Central  Google Scholar 

  8. 8.

    Hornung V, Bauernfeind F, Halle A, Samstad EO, Kono H, Rock KL, et al. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol. 2008;9:847–56.

    CAS  PubMed  PubMed Central  Google Scholar 

  9. 9.

    Petrilli V, Papin S, Dostert C, Mayor A, Martinon F, Tschopp J. Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration. Cell Death Differ. 2007;14:1583–9.

    CAS  PubMed  Google Scholar 

  10. 10.

    Bauernfeind F, Bartok E, Rieger A, Franchi L, Nunez G, Hornung V. Cutting edge: reactive oxygen species inhibitors block priming, but not activation, of the NLRP3 inflammasome. J Immunol. 2011;187:613–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  11. 11.

    Zhou R, Tardivel A, Thorens B, Choi I, Tschopp J. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol. 2010;11:136–40.

    CAS  PubMed  Google Scholar 

  12. 12.

    Zhang C, Boini KM, Xia M, Abais JM, Li X, Liu Q, et al. Activation of Nod-like receptor protein 3 inflammasomes turns on podocyte injury and glomerular sclerosis in hyperhomocysteinemia. Hypertension. 2012;60:154–62.

    CAS  PubMed  PubMed Central  Google Scholar 

  13. 13.

    Komada T, Muruve DA. The role of inflammasomes in kidney disease. Nat Rev Nephrol. 2019;15:501–20.

    PubMed  Google Scholar 

  14. 14.

    Juliana C, Fernandes-Alnemri T, Wu J, Datta P, Solorzano L, Yu JW, et al. Anti-inflammatory compounds parthenolide and Bay 11–7082 are direct inhibitors of the inflammasome. J Biol Chem. 2010;285:9792–802.

    CAS  PubMed  PubMed Central  Google Scholar 

  15. 15.

    Valino-Rivas L, Gonzalez-Lafuente L, Sanz AB, Ruiz-Ortega M, Ortiz A, Sanchez-Nino MD. Non-canonical NFkappaB activation promotes chemokine expression in podocytes. Sci Rep. 2016;6:28857.

    CAS  PubMed  PubMed Central  Google Scholar 

  16. 16.

    Viedt C, Orth SR. Monocyte chemoattractant protein-1 (MCP-1) in the kidney: does it more than simply attract monocytes? Nephrol Dial Transplant. 2002;17:2043–7.

    CAS  PubMed  Google Scholar 

  17. 17.

    Zhao Y, Chen SJ, Wang JC, Niu HX, Jia QQ, Chen XW, et al. Sesquiterpene lactones inhibit advanced oxidation protein product-induced MCP-1 expression in podocytes via an IKK/NF-kappaB-dependent mechanism. Oxid Med Cell Longev. 2015;2015:934058.

    PubMed  PubMed Central  Google Scholar 

  18. 18.

    Ridker PM, MacFadyen JG, Glynn RJ, Koenig W, Libby P, Everett BM, et al. Inhibition of Interleukin-1beta by canakinumab and cardiovascular outcomes in patients with chronic kidney disease. J Am Coll Cardiol. 2018;71:2405–14.

    CAS  PubMed  Google Scholar 

  19. 19.

    Nowak KL, Chonchol M, Ikizler TA, Farmer-Bailey H, Salas N, Chaudhry R, et al. IL-1 inhibition and vascular function in CKD. J Am Soc Nephrol. 2017;28:971–80.

    CAS  PubMed  Google Scholar 

  20. 20.

    Lidar M, Livneh A. Familial mediterranean fever: clinical, molecular and management advancements. Neth J Med. 2007;65:318–24.

    CAS  PubMed  Google Scholar 

  21. 21.

    Goldfinger SE. Colchicine for familial Mediterranean fever. N Engl J Med. 1972;287:1302.

    CAS  PubMed  Google Scholar 

  22. 22.

    Ozcakar ZB, Ozdel S, Yilmaz S, Kurt-Sukur ED, Ekim M, Yalcinkaya F. Anti-IL-1 treatment in familial Mediterranean fever and related amyloidosis. Clin Rheumatol. 2016;35:441–6.

    PubMed  Google Scholar 

  23. 23.

    Akar S, Cetin P, Kalyoncu U, Karadag O, Sari I, Cinar M, et al. Nationwide experience with off-label use of interleukin-1 targeting treatment in familial mediterranean fever patients. Arthritis Care Res (Hoboken). 2018;70:1090–4.

    CAS  Google Scholar 

  24. 24.

    Sargin G, Kose R, Senturk T. Anti-interleukin-1 treatment among patients with familial Mediterranean fever resistant to colchicine treatment. Retrospect Anal Sao Paulo Med J. 2019;137:39–44.

    Google Scholar 

  25. 25.

    Zhen J, Zhang L, Pan J, Ma S, Yu X, Li X, et al. AIM2 mediates inflammation-associated renal damage in hepatitis B virus-associated glomerulonephritis by regulating caspase-1, IL-1beta, and IL-18. Mediators Inflamm. 2014;2014:190860.

    PubMed  PubMed Central  Google Scholar 

  26. 26.

    Komada T, Chung H, Lau A, Platnich JM, Beck PL, Benediktsson H, et al. Macrophage uptake of necrotic cell DNA activates the AIM2 inflammasome to regulate a proinflammatory phenotype in CKD. J Am Soc Nephrol. 2018;29:1165–81.

    CAS  PubMed  PubMed Central  Google Scholar 

  27. 27.

    Kimkong I, Avihingsanon Y, Hirankarn N. Expression profile of HIN200 in leukocytes and renal biopsy of SLE patients by real-time RT-PCR. Lupus. 2009;18:1066–72.

    CAS  PubMed  Google Scholar 

  28. 28.

    Qiu YY, Tang LQ. Roles of the NLRP3 inflammasome in the pathogenesis of diabetic nephropathy. Pharmacol Res. 2016;114:251–64.

    CAS  PubMed  Google Scholar 

  29. 29.

    Tsai YL, Hua KF, Chen A, Wei CW, Chen WS, Wu CY, et al. NLRP3 inflammasome: pathogenic role and potential therapeutic target for IgA nephropathy. Sci Rep. 2017;7:41123.

    CAS  PubMed  PubMed Central  Google Scholar 

  30. 30.

    Mulay SR, Anders HJ. Crystal nephropathies: mechanisms of crystal-induced kidney injury. Nat Rev Nephrol. 2017;13:226–40.

    CAS  PubMed  Google Scholar 

  31. 31.

    Soares JLS, Fernandes FP, Patente TA, Monteiro MB, Parisi MC, Giannella-Neto D, et al. Gain-of-function variants in NLRP1 protect against the development of diabetic kidney disease: NLRP1 inflammasome role in metabolic stress sensing? Clin Immunol. 2018;187:46–9.

    CAS  PubMed  Google Scholar 

  32. 32.

    Song F, Ma Y, Bai XY, Chen X. The expression changes of inflammasomes in the aging rat kidneys. J Gerontol A Biol Sci Med Sci. 2016;71:747–56.

    CAS  PubMed  Google Scholar 

  33. 33.

    Yuan F, Kolb R, Pandey G, Li W, Sun L, Liu F, et al. Involvement of the NLRC4-inflammasome in diabetic nephropathy. PLoS ONE. 2016;11:e0164135.

    PubMed  PubMed Central  Google Scholar 

  34. 34.

    Russo C, Morabito F, Luise F, Piromalli A, Battaglia L, Vinci A, et al. Hyperhomocysteinemia is associated with cognitive impairment in multiple sclerosis. J Neurol. 2008;255:64–9.

    CAS  PubMed  Google Scholar 

  35. 35.

    Ostrakhovitch EA, Tabibzadeh S. Homocysteine in chronic kidney disease. Adv Clin Chem. 2015;72:77–106.

    CAS  PubMed  Google Scholar 

  36. 36.

    Xia M, Conley SM, Li G, Li PL, Boini KM. Inhibition of hyperhomocysteinemia-induced inflammasome activation and glomerular sclerosis by NLRP3 gene deletion. Cell Physiol Biochem. 2014;34:829–41.

    CAS  PubMed  PubMed Central  Google Scholar 

  37. 37.

    Abais JM, Xia M, Li G, Gehr TW, Boini KM, Li PL. Contribution of endogenously produced reactive oxygen species to the activation of podocyte NLRP3 inflammasomes in hyperhomocysteinemia. Free Radic Biol Med. 2014;67:211–20.

    CAS  PubMed  Google Scholar 

  38. 38.

    Abais JM, Zhang C, Xia M, Liu Q, Gehr TW, Boini KM, et al. NADPH oxidase-mediated triggering of inflammasome activation in mouse podocytes and glomeruli during hyperhomocysteinemia. Antioxid Redox Signal. 2013;18:1537–48.

    CAS  PubMed  PubMed Central  Google Scholar 

  39. 39.

    Abais JM, Xia M, Li G, Chen Y, Conley SM, Gehr TW, et al. Nod-like receptor protein 3 (NLRP3) inflammasome activation and podocyte injury via thioredoxin-interacting protein (TXNIP) during hyperhomocysteinemia. J Biol Chem. 2014;289:27159–68.

    CAS  PubMed  PubMed Central  Google Scholar 

  40. 40.

    Zhang Q, Conley SM, Li G, Yuan X, Li PL. Rac1 GTPase inhibition blocked podocyte injury and glomerular sclerosis during hyperhomocysteinemia via suppression of nucleotide-binding oligomerization domain-like receptor containing pyrin domain 3 inflammasome activation. Kidney Blood Press Res. 2019;44:513–32.

    CAS  PubMed  Google Scholar 

  41. 41.

    Li G, Xia M, Abais JM, Boini K, Li PL, Ritter JK. Protective action of anandamide and Its COX-2 metabolite against l-homocysteine-induced NLRP3 inflammasome activation and injury in podocytes. J Pharmacol Exp Ther. 2016;358:61–70.

    CAS  PubMed  PubMed Central  Google Scholar 

  42. 42.

    Li G, Chen Z, Bhat OM, Zhang Q, Abais-Battad JM, Conley SM, et al. NLRP3 inflammasome as a novel target for docosahexaenoic acid metabolites to abrogate glomerular injury. J Lipid Res. 2017;58:1080–90.

    CAS  PubMed  PubMed Central  Google Scholar 

  43. 43.

    Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol. 2017;12:2032–45.

    CAS  PubMed  PubMed Central  Google Scholar 

  44. 44.

    Gao P, Meng XF, Su H, He FF, Chen S, Tang H, et al. Thioredoxin-interacting protein mediates NALP3 inflammasome activation in podocytes during diabetic nephropathy. Biochim Biophys Acta. 2014;1843:2448–600.

    CAS  PubMed  Google Scholar 

  45. 45.

    Shahzad K, Bock F, Dong W, Wang H, Kopf S, Kohli S, et al. Nlrp3-inflammasome activation in non-myeloid-derived cells aggravates diabetic nephropathy. Kidney Int. 2015;87:74–84.

    CAS  PubMed  Google Scholar 

  46. 46.

    Liu Q, Zhang L, Zhang W, Hao Q, Qiu W, Wen Y, et al. Inhibition of NF-kappaB reduces renal inflammation and expression of PEPCK in type 2 diabetic mice. Inflammation. 2018;41:2018–29.

    CAS  PubMed  Google Scholar 

  47. 47.

    Lei Y, Devarapu SK, Motrapu M, Cohen CD, Lindenmeyer MT, Moll S, et al. Interleukin-1beta Inhibition for chronic kidney disease in obese mice with type 2 diabetes. Front Immunol. 2019;10:1223.

    CAS  PubMed  PubMed Central  Google Scholar 

  48. 48.

    Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377:1119–31.

    CAS  PubMed  Google Scholar 

  49. 49.

    Ridker PM, MacFadyen JG, Thuren T, Everett BM, Libby P, Glynn RJ, et al. Effect of interleukin-1beta inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390:1833–42.

    CAS  PubMed  Google Scholar 

  50. 50.

    Ridker PM, Howard CP, Walter V, Everett B, Libby P, Hensen J, et al. Effects of interleukin-1beta inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. Circulation. 2012;126:2739–48.

    CAS  PubMed  Google Scholar 

  51. 51.

    Choudhury RP, Birks JS, Mani V, Biasiolli L, Robson MD, L'Allier PL, et al. Arterial effects of canakinumab in patients with atherosclerosis and type 2 diabetes or glucose intolerance. J Am Coll Cardiol. 2016;68:1769–80.

    CAS  PubMed  PubMed Central  Google Scholar 

  52. 52.

    Gao P, He FF, Tang H, Lei CT, Chen S, Meng XF, et al. NADPH oxidase-induced NALP3 inflammasome activation is driven by thioredoxin-interacting protein which contributes to podocyte injury in hyperglycemia. J Diabetes Res. 2015;2015:504761.

    PubMed  PubMed Central  Google Scholar 

  53. 53.

    Liu Y, Xu Z, Ma F, Jia Y, Wang G. Knockdown of TLR4 attenuates high glucose-induced podocyte injury via the NALP3/ASC/Caspase-1 signaling pathway. Biomed Pharmacother. 2018;107:1393–401.

    CAS  PubMed  Google Scholar 

  54. 54.

    Yu Q, Zhang M, Qian L, Wen D, Wu G. Luteolin attenuates high glucose-induced podocyte injury via suppressing NLRP3 inflammasome pathway. Life Sci. 2019;225:1–7.

    CAS  PubMed  Google Scholar 

  55. 55.

    Chertow GM, Hsu CY, Johansen KL. The enlarging body of evidence: obesity and chronic kidney disease. J Am Soc Nephrol. 2006;17:1501–2.

    PubMed  Google Scholar 

  56. 56.

    de Vries AP, Ruggenenti P, Ruan XZ, Praga M, Cruzado JM, Bajema IM, et al. Fatty kidney: emerging role of ectopic lipid in obesity-related renal disease. Lancet Diabetes Endocrinol. 2014;2:417–26.

    PubMed  Google Scholar 

  57. 57.

    Boini KM, Xia M, Koka S, Gehr TW, Li PL. Instigation of NLRP3 inflammasome activation and glomerular injury in mice on the high fat diet: role of acid sphingomyelinase gene. Oncotarget. 2016;7:19031–44.

    PubMed  PubMed Central  Google Scholar 

  58. 58.

    Boini KM, Xia M, Abais JM, Li G, Pitzer AL, Gehr TW, et al. Activation of inflammasomes in podocyte injury of mice on the high fat diet: Effects of ASC gene deletion and silencing. Biochim Biophys Acta. 2014;1843:836–45.

    CAS  PubMed  PubMed Central  Google Scholar 

  59. 59.

    Hou XX, Dong HR, Sun LJ, Yang M, Cheng H, Chen YP. Purinergic 2X7 receptor is involved in the podocyte damage of obesity-related glomerulopathy via activating nucleotide-binding and oligomerization domain-like receptor protein 3 inflammasome. Chin Med J (Engl). 2018;131:2713–25.

    Google Scholar 

  60. 60.

    Solini A, Menini S, Rossi C, Ricci C, Santini E, Blasetti Fantauzzi C, et al. The purinergic 2X7 receptor participates in renal inflammation and injury induced by high-fat diet: possible role of NLRP3 inflammasome activation. J Pathol. 2013;231:342–53.

    CAS  PubMed  Google Scholar 

  61. 61.

    Wang W, Ding XQ, Gu TT, Song L, Li JM, Xue QC, et al. Pterostilbene and allopurinol reduce fructose-induced podocyte oxidative stress and inflammation via microRNA-377. Free Radic Biol Med. 2015;83:214–26.

    CAS  PubMed  Google Scholar 

  62. 62.

    Zhao J, Rui HL, Yang M, Sun LJ, Dong HR, Cheng H. CD36-mediated lipid accumulation and activation of NLRP3 inflammasome lead to podocyte injury in obesity-related glomerulopathy. Mediators Inflamm. 2019;2019:3172647.

    PubMed  PubMed Central  Google Scholar 

  63. 63.

    Ren Y, Wang D, Lu F, Zou X, Xu L, Wang K, et al. Coptidis Rhizoma inhibits NLRP3 inflammasome activation and alleviates renal damage in early obesity-related glomerulopathy. Phytomedicine. 2018;49:52–655.

    CAS  PubMed  Google Scholar 

  64. 64.

    Hu C, Rusin CG, Tan Z, Guagliardo NA, Barrett PQ. Zona glomerulosa cells of the mouse adrenal cortex are intrinsic electrical oscillators. J Clin Invest. 2012;122:2046–53.

    CAS  PubMed  PubMed Central  Google Scholar 

  65. 65.

    Blasi ER, Rocha R, Rudolph AE, Blomme EA, Polly ML, McMahon EG. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int. 2003;63:1791–800.

    CAS  PubMed  Google Scholar 

  66. 66.

    Chen D, Chen Z, Park C, Centrella M, McCarthy T, Chen L, et al. Aldosterone stimulates fibronectin synthesis in renal fibroblasts through mineralocorticoid receptor-dependent and independent mechanisms. Gene. 2013;531:23–30.

    CAS  PubMed  Google Scholar 

  67. 67.

    Wang B, Ding W, Zhang M, Li H, Gu Y. Rapamycin attenuates aldosterone-induced tubulointerstitial inflammation and fibrosis. Cell Physiol Biochem. 2015;35:116–25.

    PubMed  Google Scholar 

  68. 68.

    Bai M, Chen Y, Zhao M, Zhang Y, He JC, Huang S, et al. NLRP3 inflammasome activation contributes to aldosterone-induced podocyte injury. Am J Physiol Renal Physiol. 2017;312:F556–F564.

    CAS  PubMed  Google Scholar 

  69. 69.

    Zhao M, Bai M, Ding G, Zhang Y, Huang S, Jia Z, et al. Angiotensin II Stimulates the NLRP3 Inflammasome to Induce Podocyte Injury and Mitochondrial Dysfunction. Kidney Dis (Basel). 2018;4:83–94.

    Google Scholar 

  70. 70.

    Lee CK, Son SH, Park KK, Park JH, Lim SS, Chung WY. Isoliquiritigenin inhibits tumor growth and protects the kidney and liver against chemotherapy-induced toxicity in a mouse xenograft model of colon carcinoma. J Pharmacol Sci. 2008;106:444–51.

    CAS  PubMed  Google Scholar 

  71. 71.

    Wang Z, Wang N, Han S, Wang D, Mo S, Yu L, et al. Dietary compound isoliquiritigenin inhibits breast cancer neoangiogenesis via VEGF/VEGFR-2 signaling pathway. PLoS One. 2013;8:e68566.

    CAS  PubMed  PubMed Central  Google Scholar 

  72. 72.

    Kakegawa H, Matsumoto H, Satoh T. Inhibitory effects of some natural products on the activation of hyaluronidase and their anti-allergic actions. Chem Pharm Bull (Tokyo). 1992;40:1439–42.

    CAS  Google Scholar 

  73. 73.

    Tawata M, Aida K, Noguchi T, Ozaki Y, Kume S, Sasaki H, et al. Anti-platelet action of isoliquiritigenin, an aldose reductase inhibitor in licorice. Eur J Pharmacol. 1992;212:87–92.

    CAS  PubMed  Google Scholar 

  74. 74.

    Honda H, Nagai Y, Matsunaga T, Okamoto N, Watanabe Y, Tsuneyama K, et al. Isoliquiritigenin is a potent inhibitor of NLRP3 inflammasome activation and diet-induced adipose tissue inflammation. J Leukoc Biol. 2014;96:1087–100.

    PubMed  Google Scholar 

  75. 75.

    Xiong D, Hu W, Ye ST, Tan YS. Isoliquiritigenin alleviated the Ang II-induced hypertensive renal injury through suppressing inflammation cytokines and oxidative stress-induced apoptosis via Nrf2 and NF-kappaB pathways. Biochem Biophys Res Commun. 2018;506:161–8.

    CAS  PubMed  Google Scholar 

  76. 76.

    Patricia Moreno-Londono A, Bello-Alvarez C, Pedraza-Chaverri J. Isoliquiritigenin pretreatment attenuates cisplatin induced proximal tubular cells (LLC-PK1) death and enhances the toxicity induced by this drug in bladder cancer T24 cell line. Food Chem Toxicol. 2017;109:143–54.

    CAS  PubMed  Google Scholar 

  77. 77.

    Tang Y, Wang C, Wang Y, Zhang J, Wang F, Li L, et al. Isoliquiritigenin attenuates LPS-induced AKI by suppression of inflammation involving NF-kappaB pathway. Am J Transl Res. 2018;10:4141–51.

    CAS  PubMed  PubMed Central  Google Scholar 

  78. 78.

    Kriz W. Podocyte is the major culprit accounting for the progression of chronic renal disease. Microsc Res Tech. 2002;57:189–95.

    PubMed  Google Scholar 

  79. 79.

    Xiong J, Wang Y, Shao N, Gao P, Tang H, Su H, et al. The Expression and significance of NLRP3 inflammasome in patients with primary glomerular diseases. Kidney Blood Press Res. 2015;40:344–54.

    CAS  PubMed  Google Scholar 

  80. 80.

    Yan J, Li Y, Yang H, Zhang L, Yang B, Wang M, et al. Interleukin-17A participates in podocyte injury by inducing IL-1beta secretion through ROS-NLRP3 inflammasome-caspase-1 pathway. Scand J Immunol. 2018;87:e12645.

    CAS  PubMed  Google Scholar 

  81. 81.

    Yang X, Wu Y, Li Q, Zhang G, Wang M, Yang H, et al. CD36 Promotes podocyte apoptosis by activating the pyrin domain-containing-3 (NLRP3) inflammasome in primary nephrotic syndrome. Med Sci Monit. 2018;24:6832–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  82. 82.

    Wang Y, Yu F, Song D, Wang SX, Zhao MH. Podocyte involvement in lupus nephritis based on the 2003 ISN/RPS system: a large cohort study from a single centre. Rheumatol (Oxf). 2014;53:1235–44.

    CAS  Google Scholar 

  83. 83.

    Fu R, Guo C, Wang S, Huang Y, Jin O, Hu H, et al. Podocyte Activation of NLRP3 inflammasomes contributes to the development of proteinuria in lupus nephritis. Arthritis Rheumatol. 2017;69:1636–46.

    CAS  PubMed  PubMed Central  Google Scholar 

  84. 84.

    Fu R, Xia Y, Li M, Mao R, Guo C, Zhou M, et al. Pim-1 as a therapeutic target in lupus nephritis. Arthritis Rheumatol. 2019;71:1308–18.

    CAS  PubMed  Google Scholar 

  85. 85.

    Guo C, Fu R, Zhou M, Wang S, Huang Y, Hu H, et al. Pathogenesis of lupus nephritis: RIP3 dependent necroptosis and NLRP3 inflammasome activation. J Autoimmun. 2019;103:102286.

    PubMed  Google Scholar 

  86. 86.

    Wali RK, Drachenberg CI, Papadimitriou JC, Keay S, Ramos E. HIV-1-associated nephropathy and response to highly-active antiretroviral therapy. Lancet. 1998;352:783–4.

    CAS  PubMed  Google Scholar 

  87. 87.

    Haque S, Lan X, Wen H, Lederman R, Chawla A, Attia M, et al. HIV promotes NLRP3 inflammasome complex activation in murine HIV-associated nephropathy. Am J Pathol. 2016;186:347–58.

    CAS  PubMed  PubMed Central  Google Scholar 

  88. 88.

    Anders HJ. Immune system modulation of kidney regeneration–mechanisms and implications. Nat Rev Nephrol. 2014;10:347–58.

    CAS  PubMed  Google Scholar 

  89. 89.

    Swanson KV, Deng M, Ting JP. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat Rev Immunol. 2019;19:477–89.

    CAS  PubMed  Google Scholar 

  90. 90.

    Zhang G, Li Q, Wang L, Chen Y, Wang L, Zhang W. Interleukin-1beta enhances the intracellular accumulation of cholesterol by up-regulating the expression of low-density lipoprotein receptor and 3-hydroxy-3-methylglutaryl coenzyme A reductase in podocytes. Mol Cell Biochem. 2011;346:197–204.

    CAS  PubMed  Google Scholar 

  91. 91.

    Lamkanfi M. Emerging inflammasome effector mechanisms. Nat Rev Immunol. 2011;11:213–20.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by Grants from the National Natural Science Foundation of China (81974162, 81974096, 81961138007, 81770711, 81671066), program for HUST Academic Frontier Youth Team (2017QYTD20), and National Key R&D Program of China (2020YFC0845800 and 2018YFC1314000).

Author information

Affiliations

Authors

Corresponding authors

Correspondence to Xian-Fang Meng or Chun Zhang.

Ethics declarations

Conflict of interest

There are no conflicts of interests to declare.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Responsible Editor: John Di Battista.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Xiong, W., Meng, X. & Zhang, C. Inflammasome activation in podocytes: a new mechanism of glomerular diseases. Inflamm. Res. 69, 731–743 (2020). https://doi.org/10.1007/s00011-020-01354-w

Download citation

Keywords

  • Inflammasome
  • Podocytes
  • Glomerular diseases
  • NLRP3